<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-13T04:50:12Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2072/475638" metadataPrefix="qdc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2072/475638</identifier><datestamp>2025-10-13T11:42:23Z</datestamp><setSpec>com_2072_98</setSpec><setSpec>col_2072_378192</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>Antiretroviral therapy duration and immunometabolic state determine efficacy of ex vivo dendritic cell-based treatment restoring functional HIV-specific CD8+ T cells in people living with HIV</dc:title>
   <dc:creator>Calvet-Mirabent, Marta</dc:creator>
   <dc:creator>Sánchez-Cerrillo, Ildefonso</dc:creator>
   <dc:creator>Martín-Cófreces, Noa</dc:creator>
   <dc:creator>Martínez-Fleta, Pedro</dc:creator>
   <dc:creator>de la Fuente, Hortensia</dc:creator>
   <dc:creator>Tsukalov, Ilya</dc:creator>
   <dc:creator>Delgado-Arévalo, Cristina</dc:creator>
   <dc:creator>Calzada, María José</dc:creator>
   <dc:creator>de los Santos Gil, Ignacio</dc:creator>
   <dc:creator>Sanz, Jesús</dc:creator>
   <dc:creator>García-Fraile, Lucio</dc:creator>
   <dc:creator>Sánchez-Madrid, Francisco</dc:creator>
   <dc:creator>Alfranca, Arantzazu</dc:creator>
   <dc:creator>Muñoz-Fernández, María Ángeles</dc:creator>
   <dc:creator>Buzón, Maria José</dc:creator>
   <dc:creator>Martín-Gayo, Enrique</dc:creator>
   <dc:subject>HIV</dc:subject>
   <dc:subject>CD8 + T cell</dc:subject>
   <dc:subject>Dendritic cell</dc:subject>
   <dc:subject>Immunotherapy</dc:subject>
   <dc:subject>Immune exhaustion</dc:subject>
   <dc:subject>Metabolism</dc:subject>
   <dcterms:abstract>Dysfunction of CD8 + T cells in people living with HIV-1 (PLWH) receiving anti-retroviral therapy (ART) has restricted the efficacy of dendritic cell (DC)-based immunotherapies against HIV-1. Heterogeneous immune exhaustion and metabolic states of CD8 + T cells might differentially associate with dysfunction. However, specific parameters associated to functional restoration of CD8 + T cells after DC treatment have not been investigated. We studied association of restoration of functional HIV-1-specific CD8 + T cell responses after stimulation with Gag-adjuvant-primed DC with ART duration, exhaustion, metabolic and memory cell subsets profiles. HIV-1-specific CD8 + T cell responses from a larger proportion of PLWH on long-term ART (more than 10 years; LT-ARTp) improved polyfunctionality and capacity to eliminate autologous p24 + infected CD4 + T cells in vitro. In contrast, functional improvement of CD8 + T cells from PLWH on short-term ART (less than a decade; ST-ARTp) after DC treatment was limited. This was associated with lower frequencies of central memory CD8 + T cells, increased co-expression of PD1 and TIGIT and reduced mitochondrial respiration and glycolysis induction upon TCR activation. In contrast, CD8 + T cells from LT-ARTp showed increased frequencies of TIM3 + PD1 - cells and preserved induction of glycolysis. Treatment of dysfunctional CD8 + T cells from ST-ARTp with combined anti-PD1 and anti-TIGIT antibodies plus a glycolysis promoting drug restored their ability to eliminate infected CD4 + T cells. Together, our study identifies specific immunometabolic parameters for different PLWH subgroups potentially useful for future personalized DC-based HIV-1 vaccines. NIH (R21AI140930), MINECO/FEDER RETOS (RTI2018-097485-A-I00) and CIBERINF grants.</dcterms:abstract>
   <dcterms:issued>2022</dcterms:issued>
   <dc:type>Article</dc:type>
   <dc:relation>Agencia Estatal de Investigación RTI2018-097485-A-I00</dc:relation>
   <dc:relation>EBioMedicine ; Vol. 81 (june 2022)</dc:relation>
   <dc:rights>open access</dc:rights>
   <dc:rights>Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.</dc:rights>
   <dc:rights>https://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
   <dc:publisher/>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>